Research programme: glucagon receptor antagonists - Ligand Pharmaceuticals

Drug Profile

Research programme: glucagon receptor antagonists - Ligand Pharmaceuticals

Alternative Names: Cmpd G; Cmpd H; Compound G; Compound H

Latest Information Update: 13 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Metabasis Therapeutics
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Glucagon receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 12 Mar 2018 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (PO)
  • 29 Jan 2010 Ligand Pharmaceuticals acquires Metabasis Therapeutics
  • 01 Sep 2008 Pharmacodynamic data from a preclinical trial in Type-2 diabetes presented at the 44th Annual Meeting of European Association for the Study of Diabetes (EASD-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top